Hyperphosphatemia In Chronic Kidney Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Hyperphosphatemia in Chronic Kidney Disease Pipeline Products Market Report Overview
Hyperphosphatemia, that is, abnormally high serum phosphate levels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease. Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus, and rash. Treatment includes phosphate binders and diuretics.
The Hyperphosphatemia in chronic kidney disease pipeline products market research report provides comprehensive information on the therapeutics under development for Hyperphosphatemia in chronic kidney disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperphosphatemia in chronic kidney disease and features dormant and discontinued projects.
Hyperphosphatemia in Chronic Kidney Disease Pipeline Products Market Segmentation by Targets
The key targets in the Hyperphosphatemia in chronic kidney disease pipeline products market are Phosphate and Sodium/Hydrogen Exchanger 3. Phosphate is the leading target in the Hyperphosphatemia in chronic kidney disease pipeline.
Hyperphosphatemia in Chronic Kidney Disease Pipeline Products Market Analysis by Targets
For more target insights into the Hyperphosphatemia in chronic kidney disease pipeline products market, download a free report sample
Hyperphosphatemia in Chronic Kidney Disease Pipeline Products Market Segmentation by Mechanisms of Action
The mechanisms of action of Hyperphosphatemia in the chronic kidney disease pipeline drugs market are Phosphate Binder and Sodium/Hydrogen Exchanger 3 Inhibitor. Phosphate Binder is the leading MoA in the pipeline market.
Hyperphosphatemia in Chronic Kidney Disease Pipeline Products Market Analysis by Mechanisms of Action
For more MoA insights into the Hyperphosphatemia in chronic kidney disease pipeline products market, download a free report sample
Hyperphosphatemia in Chronic Kidney Disease Pipeline Products Market Segmentation by Routes of Administration
The key route of administration in Hyperphosphatemia in the chronic kidney disease pipeline drugs market is oral.
Hyperphosphatemia in Chronic Kidney Disease Pipeline Products Market Segmentation by Molecule Types
The molecule types of Hyperphosphatemia in the chronic kidney disease pipeline drugs market are small molecule and polymer. The small molecule is the leading molecule type in the Hyperphosphatemia in the chronic kidney disease pipeline drugs market.
Hyperphosphatemia in Chronic Kidney Disease Pipeline Products Market Analysis by Molecule Types
For more molecule type insights into the Hyperphosphatemia in chronic kidney disease pipeline products market, download a free report sample
Hyperphosphatemia in Chronic Kidney Disease Pipeline Products Market - Competitive Landscape
Some of the leading companies in the Hyperphosphatemia in chronic kidney disease pipeline products market are Panion & Bf Biotech Inc, Ardelyx Inc, China Nuokang Bio-Pharmaceutical Inc, Citragen Pharmaceuticals Inc, OPKO Health Inc, Shield Therapeutics Plc, Unicycive Therapeutics Inc, Vidasym Inc, and Vifor Pharma Ltd. Panion & Bf Biotech Inc is the leading company in the Hyperphosphatemia in chronic kidney disease pipeline products market and accounted for the highest number of drugs in development.
Hyperphosphatemia in Chronic Kidney Disease Pipeline Products Market Analysis by Companies
To know more about the leading Hyperphosphatemia in chronic kidney disease pipeline products market players, download a free report sample
Hyperphosphatemia in Chronic Kidney Disease Pipeline Products Market Overview
Key Targets | Phosphate and Sodium/Hydrogen Exchanger 3 |
Key MoA | Phosphate Binder and Sodium/Hydrogen Exchanger 3 Inhibitor |
Key RoA | Oral |
Key Molecule Types | Small Molecule and Polymer |
Key Companies | Panion & Bf Biotech Inc, Ardelyx Inc, China Nuokang Bio-Pharmaceutical Inc, Citragen Pharmaceuticals Inc, OPKO Health Inc, Shield Therapeutics Plc, Unicycive Therapeutics Inc, Vidasym Inc, and Vifor Pharma Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperphosphatemia in chronic kidney disease.
- The pipeline guide reviews pipeline therapeutics for Hyperphosphatemia in chronic kidney disease by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hyperphosphatemia in chronic kidney disease therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hyperphosphatemia in chronic kidney disease therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Hyperphosphatemia in chronic kidney disease
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hyperphosphatemia in chronic kidney disease.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the Hyperphosphatemia in chronic kidney disease pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
China Nuokang Bio-Pharmaceutical Inc
Citragen Pharmaceuticals Inc
OPKO Health Inc
Panion & Bf Biotech Inc
Shield Therapeutics Plc
Unicycive Therapeutics Inc
Vidasym Inc
Vifor Pharma Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Hyperphosphatemia in chronic kidney disease pipeline products market?
The key targets in the Hyperphosphatemia in chronic kidney disease pipeline products market are Phosphate and Sodium/Hydrogen Exchanger 3.
-
What are the key mechanisms of action in the Hyperphosphatemia in chronic kidney disease pipeline products market?
The key MoA in the Hyperphosphatemia in chronic kidney disease pipeline products market are Phosphate Binder and Sodium/Hydrogen Exchanger 3 Inhibitor.
-
What is the key route of administration in the Hyperphosphatemia in chronic kidney disease pipeline products market?
The key RoA in the Hyperphosphatemia in chronic kidney disease pipeline products market is oral.
-
What are the key molecule types in the Hyperphosphatemia in chronic kidney disease pipeline products market?
The key molecule types in the Hyperphosphatemia in chronic kidney disease pipeline products market are small molecule and polymer.
-
Which are the leading companies in the Hyperphosphatemia in chronic kidney disease pipeline products market?
Some of the leading companies in the Hyperphosphatemia in chronic kidney disease pipeline products market are Panion & Bf Biotech Inc, Ardelyx Inc, China Nuokang Bio-Pharmaceutical Inc, Citragen Pharmaceuticals Inc, OPKO Health Inc, Shield Therapeutics Plc, Unicycive Therapeutics Inc, Vidasym Inc, and Vifor Pharma Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.